Search
Veracyte Inc
VCYTAdd to Watchlist
41.250USD
-1.350-3.17%
Close 08-14 16:00（ET）Quotes delayed by 15 min
3.32BMarket Cap
37.00P/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Veracyte Inc is 8.46, ranking 126 out of 387 in the Biotechnology & Medical Research industry. The average price target is 48.00, with a high of 57.00 and a low of 43.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
57.333
Target Price
+28.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Veracyte Inc
VCYT
13
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Veracyte Inc's expected revenue for the next quarter?
Veracyte Inc's expected revenue is 147.55M.
What is Veracyte Inc's price target?
Analysts forecast that Veracyte Inc's price target is USD 48.00, with the highest forecast at USD 57.00 and the lowest forecast at USD 43.00.
How have Veracyte IncVCYT's recent earnings per share performed?
The market expectation was USD 0.32, while Veracyte IncVCYT's earnings per share (EPS) for the previous quarter was USD 0.36. EPS for the next quarter is expected at USD 0.25.
What is the analyst rating for Veracyte Inc?
Based on the ratings of Veracyte Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.